Generate Biomedicines Inc (GENB) Stock Analysis
Verdict: AVOID
Generative AI platform potential is overshadowed by a ~7-month cash runway ($121.7M cash vs $200.6M burn) and high dilution risk.
Investment score: 37/100
Analysis as of
Is Generate Biomedicines Inc stock worth reviewing? AI model thesis
The AI model evaluates Generate Biomedicines (GENB) as an AVOID due to severe cash burn ($204.1M FCF loss in 2025) leaving only ~7.3 months of cash runway ($121.7M cash) and impending dilution risk, despite strong technical momentum (+15.01% daily rally to $20.38).
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Generate Biomedicines Inc opportunities and risks
What speaks for GENB
- Proprietary Generative AI Drug Platform
What speaks against GENB
- Critical Cash Runway Cliff (~7.3 Months)
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| GENB | n/a | 193.0x | n/a | 75.8% | -950.7% | -5.5% |
| SLS | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.1% |
| NRIX | n/a | 76.1x | n/a | -165.5% | -928.4% | -10.9% |
| CDNA | 23.6x | 5.7x | 146.1x | 70.6% | 24.2% | 3.2% |
| RARE | n/a | 3.6x | n/a | 83.1% | -81.8% | -18.8% |
| PGEN | n/a | 30.3x | n/a | 89.6% | -184.0% | -4.5% |
| Peer median | n/a | 5.7x | n/a | 70.6% | -81.8% | -4.5% |
Frequently asked questions about Generate Biomedicines Inc (GENB)
Is GENB stock a good investment?
The cached TradeMates AI model rates Generate Biomedicines Inc as AVOID with an investment score of 37/100. The AI model evaluates Generate Biomedicines (GENB) as an AVOID due to severe cash burn ($204.1M FCF loss in 2025) leaving only ~7.3 months of cash runway ($121.7M cash) and impending dilution risk, despite strong technical momentum (+15.01% daily rally to $20.38). This is algorithmic model output, not personal investment advice.
Is GENB stock a buy?
The TradeMates model verdict for GENB is AVOID with an investment score of 37/100. Treat this as a model signal to review, not a personal buy recommendation.